Cholesterol uptake capacity of HDL in culture medium of fresh primary human hepatocytes: an in vitro system for screening anti-atherosclerosis drugs focused on HDL functions.

objectiveRemoving excess cholesterol from atherosclerotic plaques is a crucial function of high-density lipoprotein (HDL). Compared to HDL cholesterol, cholesterol efflux capacity (CEC) is a better indicator of cardiovascular disease risk. However, this approach has several practical disadvantages, such as CEC assay requires cultured cells and takes several days to perform. Recently, we developed a simpler cell-free assay to assess the cholesterol uptake capacity (CUC), a new HDL functionality metric. In this study, we combined the HDL-CUC assay with PXB-cells LA, primary human hepatocytes derived from the humanized mouse liver, to investigate whether the CUC of HDL in the culture medium reflects the eicosapentaenoic acid (EPA) effects on HDL functionality.

resultsThe CUC of HDL in the culture medium of PXB-cells LA was measured using the automated immunoassay system HI-1000. Adding EPA to the culture medium did not alter albumin or hepatic triglyceride lipase levels, confirming no significant EPA-induced damage to the hepatocytes. However, as reported for CEC, EPA significantly increased the CUC in a dose-dependent manner, highlighting the potential of EPA as a therapeutic candidate for patients with low CUC. Thus, the proposed assay system could be used for in vitro drug screening that improves HDL functionality.